TN2011000040A1 - Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists - Google Patents

Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists

Info

Publication number: TN2011000040A1
Authority: TN; Tunisia
Prior art keywords: receptor antagonists; crf; amide derivatives; cyclohexyl amide; cyclohexyl
Prior art date: 2008-08-07

Application number

TN2011000040A

Other languages

English (en)

Inventor

Anny-Odile Colson

Andrew James Culshaw

Lisa Rooney

Emily Stanley

Lilya Sviridenko

David Beattie

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-07

Filing date

2011-01-26

Publication date

2012-09-05

2011-01-26 Application filed by Novartis Ag filed Critical Novartis Ag

2012-09-05 Publication of TN2011000040A1 publication Critical patent/TN2011000040A1/fr

Links

PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical class NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 title abstract 2
239000002464 receptor antagonist Substances 0.000 title abstract 2
229940044551 receptor antagonist Drugs 0.000 title abstract 2
108091005471 CRHR1 Proteins 0.000 title 1
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Psychology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Pregnancy & Childbirth (AREA)
Hematology (AREA)

TN2011000040A 2008-08-07 2011-01-26 Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists TN2011000040A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP08162006		2008-08-07
US20513909P	2009-01-14	2009-01-14
EP09150543		2009-01-14
PCT/EP2009/060150 WO2010015655A1 (fr)	2008-08-07	2009-08-05	Dérivés de cyclohexylamide et leur utilisation en tant qu'antagonistes des récepteurs de crf-1

Publications (1)

Publication Number	Publication Date
TN2011000040A1 true TN2011000040A1 (en)	2012-09-05

Family

ID=41653509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000040A TN2011000040A1 (en)	2008-08-07	2011-01-26	Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists

Country Status (25)

Country	Link
US (3)	US8273900B2 (fr)
EP (1)	EP2323970B1 (fr)
JP (1)	JP5527745B2 (fr)
KR (1)	KR101302796B1 (fr)
CN (1)	CN102143940B (fr)
AR (1)	AR072969A1 (fr)
AU (1)	AU2009279089B2 (fr)
BR (1)	BRPI0917574A2 (fr)
CA (1)	CA2732887A1 (fr)
CO (1)	CO6351776A2 (fr)
EA (1)	EA020921B1 (fr)
EC (1)	ECSP11010814A (fr)
ES (1)	ES2582576T3 (fr)
HN (1)	HN2011000372A (fr)
IL (1)	IL210834A0 (fr)
MA (1)	MA32534B1 (fr)
MX (1)	MX2011001375A (fr)
MY (1)	MY151568A (fr)
PE (1)	PE20110237A1 (fr)
SV (1)	SV2011003832A (fr)
TN (1)	TN2011000040A1 (fr)
TW (1)	TW201011001A (fr)
UY (1)	UY32036A (fr)
WO (1)	WO2010015655A1 (fr)
ZA (1)	ZA201100513B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8273900B2 (en) *	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
WO2011092293A2 (fr) *	2010-02-01	2011-08-04	Novartis Ag	Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
EP2531490B1 (fr) *	2010-02-02	2014-10-15	Novartis AG	Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
NZ700332A (en)	2010-03-30	2017-06-30	Verseon Corp	Multisubstituted aromatic compounds as inhibitors of thrombin
US9035022B2 (en)	2010-12-22	2015-05-19	Salk Institute For Biological Studies	Cyclic CRF antagonist peptides
UY34094A (es)	2011-05-27	2013-01-03	Novartis Ag	Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
BR112014026210A2 (pt)	2012-05-03	2017-06-27	Novartis Ag	derivados de sal l-malato de 2,7-diaza-espiro[4.5]dec-7-il e formas cristalinas dos mesmos como agonistas do receptor de grelina
US9814723B2 (en) *	2013-02-23	2017-11-14	Lixin Zhang	Compositions and methods for prophylaxis and therapy for Meniere's disease
SG11201506757TA (en) *	2013-03-15	2015-09-29	Verseon Corp	Halogenopyrazoles as inhibitors of thrombin
CN110179795A (zh)	2013-03-15	2019-08-30	维颂公司	作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
SI3096756T1 (sl)	2014-01-21	2024-09-30	Neurocrine Biosciences, Inc.	CRF1 receptorski antagonisti za zdravljenje kongenitalne adrenalne hiperplazije
US10987322B2 (en)	2014-06-06	2021-04-27	Flexus Biosciences, Inc.	Immunoregulatory agents
CA2960790A1 (fr)	2014-09-17	2016-03-24	Verseon Corporation	Composes de pyridone substituee par pyrazolyl en tant qu'inhibiteurs de serine protease
MX2017005462A (es)	2014-11-05	2017-07-28	Flexus Biosciences Inc	Agentes inmunorreguladores.
UY36391A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
BR112017018092A2 (pt)	2015-02-27	2018-04-10	Verseon Corp	composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio.
WO2019025931A1 (fr)	2017-07-31	2019-02-07	Novartis Ag	Utilisation de mavoglurant dans la réduction de l'utilisation de cocaïne ou dans la prévention d'une rechute dans l'utilisation de cocaïne
US11230542B2 (en)	2017-12-13	2022-01-25	Praxis Biotech LLC	Inhibitors of integrated stress response pathway
KR102590854B1 (ko) *	2018-04-09	2023-10-18	라퀄리아 파마 인코포레이티드	Crhr2 길항제로서의 축합 환상 요소 유도체
KR20210021519A (ko)	2018-06-05	2021-02-26	프락시스 바이오테크 엘엘씨	통합 스트레스 반응 경로의 저해제
BR112021010847A2 (pt)	2018-12-07	2021-09-08	Neurocrine Biosciences Inc.	Antagonista de receptor de crf1, formulações farmacêuticas e formas sólidas das mesmas para o tratamento de hiperplasia adrenal congênita
EP3982965A4 (fr)	2019-06-12	2023-01-25	Praxis Biotech LLC	Modulateurs de la voie de réponse intégrée au stress
EP3983378A4 (fr) *	2019-06-12	2023-12-13	Praxis Biotech LLC	Inhibiteurs de la voie de réponse intégrée au stress
JP2023545256A (ja) *	2020-09-30	2023-10-27	ラクオリア創薬株式会社	Ｃｒｈｒ２拮抗薬としての３－ヒドロキシオキシインドール誘導体

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2417216A1 (de)	1974-04-09	1975-11-06	Basf Ag	Fungizide
DE2828265A1 (de)	1978-06-28	1980-01-17	Bayer Ag	Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen acetaniliden
DE3600288A1 (de)	1986-01-08	1987-07-16	Bayer Ag	Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3618004A1 (de)	1986-05-28	1987-12-03	Bayer Ag	Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
JP2770497B2 (ja)	1988-11-24	1998-07-02	吉富製薬株式会社	トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
WO1990005723A1 (fr)	1988-11-24	1990-05-31	Yoshitomi Pharmaceutical Industries, Ltd.	Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
JP2864489B2 (ja)	1991-02-27	1999-03-03	吉富製薬株式会社	喘息治療剤
DE4107571A1 (de)	1991-03-07	1992-11-19	Diagnostikforschung Inst	Amid-chelate, deren metallkomplexe sowie ihre verwendung in diagnostik und therapie
EP0524439A1 (fr)	1991-07-24	1993-01-27	F.Hoffmann-La Roche & Co. Aktiengesellschaft	Dérivés du cyclohexane et du tétrahydropyranne et compositions antifongiques contenant ces dérivés
KR0133372B1 (ko)	1991-09-06	1998-04-23	고야 다다시	4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
WO1993011731A2 (fr)	1991-12-12	1993-06-24	The Trustees Of The University Of Pennsylvania	Peptidomimetisme alicyclique
JP3218356B2 (ja)	1993-03-31	2001-10-15	ヤンマー農機株式会社	管理機
JPH0841006A (ja)	1994-08-05	1996-02-13	Nisshin Flour Milling Co Ltd	ジウレア誘導体
US6107300A (en) *	1996-03-27	2000-08-22	Dupont Pharmaceuticals	Arylamino fused pyrimidines
CA2257950A1 (fr)	1996-06-28	1998-01-08	Merck & Co., Inc.	Promedicaments antagonistes de recepteurs de fibrinogenes
SE9802208D0 (sv)	1998-06-22	1998-06-22	Astra Pharma Inc	Novel compounds
SE9802206D0 (sv)	1998-06-22	1998-06-22	Astra Pharma Inc	Novel compounds
US6673812B1 (en)	1998-08-17	2004-01-06	Senju Pharmaceutical Co., Ltd.	Preventives/remedies for glaucoma
KR100704704B1 (ko)	1999-03-25	2007-04-09	미쯔비시 웰 파마 가부시키가이샤	간질성 폐렴·폐섬유증의 예방·치료약
AU3987800A (en)	1999-04-22	2000-11-10	Mitsubishi Pharma Corporation	Preventives/remedies for angiostenosis
WO2000064478A1 (fr)	1999-04-27	2000-11-02	Mitsubishi Pharma Corporation	Medicaments destines a soigner et a prevenir les maladies du foie
US6291499B1 (en)	1999-10-29	2001-09-18	Merck & Co., Inc.	2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US20040038855A1 (en) *	1999-12-30	2004-02-26	Salon John A.	DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
GB0002100D0 (en)	2000-01-28	2000-03-22	Novartis Ag	Organic compounds
EP1289561A2 (fr)	2000-01-28	2003-03-12	National University Of Singapore	Nouveaux ligands et procedes de preparation correspondants
US6344733B1 (en)	2000-01-31	2002-02-05	Snap-On Technologies, Inc.	Portable jump-starting battery pack with charge monitoring system
US6915807B2 (en)	2000-02-23	2005-07-12	Young Sik Choi	Hair setting device
WO2001062718A1 (fr)	2000-02-25	2001-08-30	Japan Tobacco, Inc.	Dérivé de benzamide et utilisation de celui-ci
US6720341B2 (en) *	2000-03-31	2004-04-13	Mitsubishi Pharma Corporation	Preventives/remedies for kidney diseases
DE60141963D1 (de)	2000-06-23	2010-06-10	Mitsubishi Tanabe Pharma Corp	Antitumoreffekt-verstärker
IL153119A0 (en)	2000-06-27	2003-06-24	Genelabs Tech Inc	Novel compounds possessing antibacterial, antifungal or antitumor activity
US6720324B2 (en) *	2000-07-05	2004-04-13	Synaptic Pharmaceutical Corporation	Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MXPA03001269A (es)	2000-08-16	2003-06-09	Hoffmann La Roche	Nuevos derivados de aminociclohexano.
AU2002225767A1 (en)	2000-11-28	2002-06-11	Guilford Pharmaceuticals Inc.	Bisubstituted carbocyclic cyclophilin binding compounds and theirus
EP1217000A1 (fr)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibiteurs du factor Xa et factor VIIa
JP4204326B2 (ja)	2001-04-11	2009-01-07	千寿製薬株式会社	視覚機能障害改善剤
US7199147B2 (en)	2001-06-12	2007-04-03	Dainippon Sumitomo Pharma Co., Ltd.	Rho kinase inhibitors
CA2460594A1 (fr)	2001-10-01	2003-04-10	Taisho Pharmaceutical Co., Ltd.	Antagonistes du recepteur de la mch
AU2002361846A1 (en)	2001-12-21	2003-07-15	Bayer Pharmaceuticals Corporation	Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002364209A1 (en)	2001-12-26	2003-07-24	Genelabs Technologies, Inc.	Polyamide derivatives possessing antibacterial, antifungal or antitumor activity
PL372548A1 (en)	2002-03-28	2005-07-25	Tanabe Seiyaku Co, Ltd.	Benzofuran derivative
WO2003104233A1 (fr)	2002-06-07	2003-12-18	Altana Pharma Ag	Derives de 4,5-dihydro-imidazo (4,5,1-ij) quinoline-6-ones et utilisation de ceux-ci en tant qu'inhibiteurs de la poly (adp-ribosyl) transferase (parp)
US20040072802A1 (en) *	2002-10-09	2004-04-15	Jingwu Duan	Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
JP2006514628A (ja)	2002-11-21	2006-05-11	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	Ｃｒｆ変調剤としてのピラジン化合物
RU2341518C2 (ru) *	2002-12-02	2008-12-20	Ф.Хоффманн-Ля Рош Аг	Производные индазола как антагонисты крф
ATE405269T1 (de)	2002-12-13	2008-09-15	Smithkline Beecham Corp	Cyclohexylverbindungen als ccr5-antagonisten
JP2004203748A (ja)	2002-12-24	2004-07-22	Kissei Pharmaceut Co Ltd	新規なイミダゾ［１，２−ｃ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
MXPA05007394A (es)	2003-01-08	2005-09-12	Chiron Corp	Agentes antibacterianos.
JP2004238296A (ja)	2003-02-04	2004-08-26	Kissei Pharmaceut Co Ltd	新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1464335A3 (fr)	2003-03-31	2007-05-09	Taisho Pharmaceutical Co. Ltd.	Derivés de quinolines, tetrahydroquinolines et pyrimidines comme antagonistes du MCH
JP2004315511A (ja)	2003-03-31	2004-11-11	Taisho Pharmaceut Co Ltd	Ｍｃｈ受容体アンタゴニスト
JP4273821B2 (ja)	2003-04-21	2009-06-03	ヤマハ株式会社	音声データ処理プログラム
EP1667962A1 (fr)	2003-09-22	2006-06-14	F. Hoffmann-La Roche Ag	Derives de cyclohexyle substitues par aminoalkylamide
JP4289264B2 (ja)	2003-09-26	2009-07-01	田辺三菱製薬株式会社	医薬組成物
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
CN1906198A (zh) *	2003-11-25	2007-01-31	布里斯托尔-迈尔斯斯奎布药品公司	吡唑并[1,5－α]－1,3,5－三嗪和其中间物的制备方法
GB0403038D0 (en)	2004-02-11	2004-03-17	Novartis Ag	Organic compounds
CN1976905A (zh)	2004-03-30	2007-06-06	大正制药株式会社	嘧啶衍生物以及与其应用有关的治疗方法
EA200700117A1 (ru)	2004-06-24	2007-06-29	Инсайт Корпорейшн	N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
DK1775298T3 (da) *	2004-07-01	2013-05-21	Daiichi Sankyo Co Ltd	Thienopyrazolderivat med PDE7-inhibitorisk aktivitet
JP2008505910A (ja)	2004-07-08	2008-02-28	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
WO2006023844A2 (fr)	2004-08-20	2006-03-02	Entremed, Inc.	Compositions et procedes comportant des antagonistes de recepteur active par la proteinase
AR051094A1 (es) *	2004-09-20	2006-12-20	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US20080090863A1 (en)	2004-09-30	2008-04-17	Taisho Pharmaceutical Co., Ltd.	Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
JP2006124387A (ja)	2004-09-30	2006-05-18	Taisho Pharmaceut Co Ltd	新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
TW200621759A (en)	2004-10-29	2006-07-01	Banyu Pharma Co Ltd	Novel aminopyridine derivatives having aurora A selective inhibitory action
US7491720B2 (en) *	2004-10-29	2009-02-17	Banyu Pharmaceutical Co., Ltd.	Aminopyridine derivatives having Aurora A selective inhibitory action
JPWO2006057270A1 (ja)	2004-11-26	2008-06-05	旭化成ファーマ株式会社	含窒素３環化合物
GB0510141D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B3
GB0510139D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B1
JP2007091649A (ja)	2005-09-29	2007-04-12	Taisho Pharmaceut Co Ltd	ピリミジン誘導体及びその使用に関連する治療方法
WO2007063839A1 (fr)	2005-11-30	2007-06-07	Shionogi & Co., Ltd.	Derives de cyclohexane
DE102005061428A1 (de)	2005-12-22	2007-08-16	Grünenthal GmbH	Substituierte Cyclohexylmethyl-Derivate
JPWO2007083689A1 (ja)	2006-01-19	2009-06-11	株式会社レナサイエンス	プラスミノーゲンアクチベーターインヒビター−１阻害剤
JP2007291087A (ja)	2006-03-29	2007-11-08	Taisho Pharmaceut Co Ltd	ピリジン誘導体及びその使用に関連する治療法
TW200815351A (en)	2006-05-02	2008-04-01	Astrazeneca Ab	Novel compounds
CA2658362A1 (fr)	2006-06-29	2008-01-03	Alantos Pharmaceuticals Holding, Inc.	Inhibiteurs des metalloproteases
JP5087631B2 (ja)	2006-10-31	2012-12-05	エフ．ホフマン−ラロシュアーゲー	５−ｈｔ２ａ及びｄ３受容体のデュアルモジュレーターのエーテル誘導体
JP5205274B2 (ja)	2006-11-22	2013-06-05	日本農薬株式会社	新規なピラゾール誘導体、有害生物防除剤及びその使用方法
WO2008065500A2 (fr)	2006-11-30	2008-06-05	Pfizer Products Inc.	Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
ES2409090T3 (es)	2006-12-08	2013-06-24	Millennium Pharmaceuticals, Inc.	Formulaciones de dosis unitaria y métodos para el tratamiento de trombosis con un inhibidor oral del factor Xa
JP2010513519A (ja)	2006-12-22	2010-04-30	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	キナーゼインヒビター活性を有するある種のピラゾリン誘導体
PE20081785A1 (es)	2007-02-19	2009-01-12	Novartis Ag	Derivados de ciclohexil-amida del acido aril carboxilico
WO2008124000A2 (fr)	2007-04-02	2008-10-16	Ligand Pharmaceuticals Incorporated	Dérivés de thiazole utilisés comme composés modulateurs de récepteurs d'androgènes
CN101765585B (zh)	2007-06-12	2017-03-15	尔察祯有限公司	抗菌剂
US20090270452A1 (en)	2008-04-18	2009-10-29	Arete Therapeutics, Inc.	Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
CA2722139C (fr)	2008-04-23	2017-04-11	Rigel Pharmaceuticals, Inc.	Composes de carboxamide pour le traitement de troubles metaboliques
US20110039860A1 (en)	2008-05-07	2011-02-17	Cangming Yang	Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
CA2724214A1 (fr)	2008-05-13	2009-11-19	Boehringer Ingelheim International Gmbh	Derives d'acide carboxylique alicyclique de benzomorphanes et echafaudages afferents, medicaments contenant ces composes, et utilisation de ceux-ci
EP2303862B1 (fr)	2008-05-27	2016-08-24	The Board of Regents of The University of Texas System	Inhibiteurs de signalisation de la protéine wnt
US20090298834A1 (en) *	2008-06-02	2009-12-03	Hassan Pajouhesh	4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
WO2009153720A1 (fr)	2008-06-18	2009-12-23	Pfizer Limited	Dérivés de nicotinamide
US7994203B2 (en)	2008-08-06	2011-08-09	Novartis Ag	Organic compounds
US8273900B2 (en)	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
WO2010025043A1 (fr)	2008-08-29	2010-03-04	Arete Therapeutics, Inc.	Utilisation d'inhibiteurs de l'époxyde hydrolase soluble dans le traitement de maladies vasculaires inflammatoires
WO2010048149A2 (fr)	2008-10-20	2010-04-29	Kalypsys, Inc.	Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
US8598209B2 (en)	2008-10-31	2013-12-03	Merck Sharp & Dohme Corp.	P2X3, receptor antagonists for treatment of pain
WO2010085246A1 (fr)	2009-01-21	2010-07-29	Praecis Pharmaceuticals Inc	Dérivés de 2,4-diamino-1,3,5-triazine et de 4,6-diamino-pyrimidine et leur emploi en tant qu'inhibiteurs d'aggrécanase
BRPI1007968A2 (pt)	2009-02-12	2016-10-04	Astellas Pharma Inc	derivado de anel hetero

2009
- 2009-07-31 US US12/462,318 patent/US8273900B2/en not_active Expired - Fee Related
- 2009-08-05 ES ES09804572.7T patent/ES2582576T3/es active Active
- 2009-08-05 JP JP2011521570A patent/JP5527745B2/ja not_active Expired - Fee Related
- 2009-08-05 CA CA2732887A patent/CA2732887A1/fr not_active Abandoned
- 2009-08-05 PE PE2011000132A patent/PE20110237A1/es not_active Application Discontinuation
- 2009-08-05 AR ARP090102998A patent/AR072969A1/es unknown
- 2009-08-05 CN CN200980134704.5A patent/CN102143940B/zh not_active Expired - Fee Related
- 2009-08-05 KR KR1020117005153A patent/KR101302796B1/ko active Active
- 2009-08-05 MX MX2011001375A patent/MX2011001375A/es active IP Right Grant
- 2009-08-05 WO PCT/EP2009/060150 patent/WO2010015655A1/fr active Application Filing
- 2009-08-05 EP EP09804572.7A patent/EP2323970B1/fr active Active
- 2009-08-05 BR BRPI0917574A patent/BRPI0917574A2/pt not_active IP Right Cessation
- 2009-08-05 MY MYPI20110353 patent/MY151568A/en unknown
- 2009-08-05 AU AU2009279089A patent/AU2009279089B2/en not_active Ceased
- 2009-08-05 US US13/057,015 patent/US8614213B2/en active Active
- 2009-08-05 UY UY0001032036A patent/UY32036A/es not_active Application Discontinuation
- 2009-08-05 EA EA201100306A patent/EA020921B1/ru not_active IP Right Cessation
- 2009-08-06 TW TW098126599A patent/TW201011001A/zh unknown
2011
- 2011-01-20 ZA ZA2011/00513A patent/ZA201100513B/en unknown
- 2011-01-24 IL IL210834A patent/IL210834A0/en unknown
- 2011-01-26 TN TN2011000040A patent/TN2011000040A1/fr unknown
- 2011-02-01 CO CO11011426A patent/CO6351776A2/es not_active Application Discontinuation
- 2011-02-01 MA MA33574A patent/MA32534B1/fr unknown
- 2011-02-07 SV SV2011003832A patent/SV2011003832A/es not_active Application Discontinuation
- 2011-02-07 HN HN2011000372A patent/HN2011000372A/es unknown
- 2011-02-07 EC EC2011010814A patent/ECSP11010814A/es unknown
2013
- 2013-11-22 US US14/087,773 patent/US20140088105A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HN2011000372A (es)	2013-05-20
EA020921B1 (ru)	2015-02-27
MX2011001375A (es)	2011-03-15
KR101302796B1 (ko)	2013-09-02
ZA201100513B (en)	2011-10-26
KR20110038730A (ko)	2011-04-14
AU2009279089B2 (en)	2012-08-23
MY151568A (en)	2014-06-13
AU2009279089A1 (en)	2010-02-11
TW201011001A (en)	2010-03-16
US8614213B2 (en)	2013-12-24
EP2323970B1 (fr)	2016-04-20
CA2732887A1 (fr)	2010-02-11
US8273900B2 (en)	2012-09-25
CO6351776A2 (es)	2011-12-20
AR072969A1 (es)	2010-10-06
ES2582576T3 (es)	2016-09-13
EP2323970A1 (fr)	2011-05-25
WO2010015655A1 (fr)	2010-02-11
US20140088105A1 (en)	2014-03-27
JP5527745B2 (ja)	2014-06-25
IL210834A0 (en)	2011-04-28
BRPI0917574A2 (pt)	2015-11-17
JP2011529944A (ja)	2011-12-15
US20110152261A1 (en)	2011-06-23
EA201100306A1 (ru)	2012-01-30
US20100035898A1 (en)	2010-02-11
CN102143940A (zh)	2011-08-03
ECSP11010814A (es)	2011-03-31
MA32534B1 (fr)	2011-08-01
SV2011003832A (es)	2011-07-05
CN102143940B (zh)	2014-04-16
UY32036A (es)	2010-03-26
PE20110237A1 (es)	2011-05-12

Publication	Publication Date	Title
TN2011000040A1 (en)	2012-09-05	Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
TN2009000181A1 (en)	2010-10-18	Agonist trkb antibodies and uses thereof
ATE496051T1 (de)	2011-02-15	Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
PL396375A1 (pl)	2012-04-23	Kompozycje obejmujące arylopirazol i/lub formamidynę, sposoby i zastosowania je obejmujące
MX338336B (es)	2016-04-07	Polipeptidos de insulina modificados y sus usos.
EA201170227A1 (ru)	2011-06-30	Имидазолкарбоксамиды
HK1203980A1 (en)	2015-11-06	Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb
MX344166B (es)	2016-12-07	Leptina-polipeptidos modificados y sus usos.
IL210773A0 (en)	2011-03-31	Neuropeptide-2 receptor (y-2r) agonists and uses thereof
DE602007004999D1 (de)	2010-04-08	1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
HK1142608A1 (en)	2010-12-10	5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
IL212364A0 (en)	2011-06-30	Neuropeptide-2-receptor (y-2r) agonists and uses thereof
IL185726A0 (en)	2008-01-06	Benzimidazole derivative and use as angiotensin ii antagonist
IL207649A0 (en)	2010-12-30	Substituted (pyrazolylcarbonyl) imidazolidinones and their use
SG149831A1 (en)	2009-02-27	Benzimidazole derivatives
IL209718A0 (en)	2011-02-28	Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof
ZA200709002B (en)	2009-01-28	Benzimidazole derivative and use as angiotensin II antagonist
UA105771C2 (uk)	2014-06-25	Похідні циклогексиламіду та їх застосування як антагоністів рецептора crf-1
CL2012000355A1 (es)	2012-08-31	Compuestos derivados de 4-amino-butenamida; composicion farmaceutica; y uso en el tratamiento de la epoc.
CL2009000317A1 (es)	2010-02-26	Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad.
AU320425S (en)	2008-07-25	Ratchet clip
UA29770U (ru)	2008-01-25	Применение мигрепина как вещества с противоболевыми свойствами
UA50734U (en)	2010-06-25	use of interleukin-1 (ARIL-1) receptor antagonist as agent of antiamnestic, anticonvulsant and anxyolitic action
AU320681S (en)	2008-08-12	An extension
AU320680S (en)	2008-08-12	An extension clip